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Introduction and background
===========================

Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), the causative agent of COVID-19 (coronavirus disease-2019), first originated from Wuhan in the Hubei province of China during late December of 2019. It started as an outbreak which led to an epidemic with 44,672 confirmed cases in China by February 14, 2020, with 2.3% reported mortality rate, which was comparatively lower than the previously known epidemics caused by human coronaviruses (Severe Acute Respiratory Syndrome Coronavirus \[SARS-CoV\] and the Middle East Respiratory Syndrome Coronavirus \[MERS-CoV\]) in 2003 and 2012, respectively \[[@REF1]\]. It rapidly spread outside of China to the rest of the world, mainly through human-to-human transmission by respiratory droplets or possibly through the fecal-oral route, and consequently, the World Health Organization (WHO) declared COVID-19 as a global pandemic on March 11, 2020 \[[@REF2]\]. The infection presents most commonly as fever, dry cough, shortness of breath, sore throat, and diarrhea with severe respiratory involvement in patients with advanced age (over age 80). The overall case fatality rate in this age group is about 14.3% \[[@REF3]\]. The severity of this disease is characterized by severe pneumonia, respiratory failure requiring mechanical ventilation, sepsis, myocardial injury, multi-organ failure, and mortality increases in patients having underlying comorbidities such as cardiovascular disease, diabetes, and chronic respiratory disease \[[@REF4]\]. Given the rapid spread of the virus, researchers across multiple nations have dedicated themselves to better understand the virus and disease pathophysiology and develop effective drugs and preventive vaccines.

While new treatment options are being sought out, one of the main areas of focus has been trying to repurpose the existing drugs to fight against COVID-19. Several drugs are being tested in the trials, and the United States Food and Drugs Administration (FDA) has given Emergency Use Authorization (EUA) for remdesivir to treat COVID-19 patients on May 1, 2020 \[[@REF5]\].

Review
======

The clinical management of COVID-19 patients is focused on alleviating clinical symptoms by general and symptom-specific supportive care \[[@REF6]\]. Potential therapeutic options against COVID-19 include molecules binding to the virus, inhibitors that can target specific enzymes involved in viral replication or viral transcription. Small-molecule inhibitors can target helicase, essential proteases, or other proteins of the virus, and host cell protease inhibitor \[[@REF7]\]. Based on the sequencing of the entire genome and the information coupled with protein structure modeling, the research community has been able to rapidly respond with a proposed list of antiviral agents with potential therapeutic efficacy in the treatment of COVID-19. The investigational drugs together with their potential mechanisms of actions and other specific characteristics are summarized in Table [1](#TAB1){ref-type="table"}.

###### Drugs repurposed for the treatment of COVID-19 under clinical trials

RNA, Ribonucleic acid; mRNA, Messenger RNA; HIV, Human immunodeficiency virus; JAK, Janus kinase; ACE2, Angiotensin-converting enzyme 2; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; COVID-19, Coronavirus disease 2019

  -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------
  Drug                       Mechanism of Action (MOA)                                                                                                                                                                                          Disease indication
  Remdesivir                 Metabolizes into its active form GS-441524, interferes with RNA polymerase and decreases  viral RNA production; may inhibit viral nucleotide synthesis to stop viral replication                                   Ebola virus infection
  Corticosteroids            Binds with cytoplasmic receptors and alters the transcription of mRNA and reduce the production of inflammatory mediators responsible for the disease.                                                             Hyperglycemia, adrenal suppression
  Favipiravir  (Favilavir)   RNA replicase; a purine nucleoside that acts as an alternate substrate leading to lethal RNA transversion mutations, producing a nonviable viral phenotype                                                         Viral infections
  Ribavirin                  Metabolized to purine RNA to stop viral synthesis and viral mRNA capping                                                                                                                                           RSV infection, hepatitis C
  Umifenovir (Arbidol)       Inhibits membrane fusion and prevents contact between virus and host cell; an inhibitor that may disrupt the binding of viral envelope protein to host cells and thus may prevent viral entry to the target cell   Influenza
  Lopinavir (LPV)            Viral protease inhibitor that may inhibit the viral replication                                                                                                                                                    HIV infection
  Ritonavir (RTV)            Pharmacokinetic profile enhancer of other protease inhibitors                                                                                                                                                       
  Baricitinib                Inhibitor of Janus kinase (JAK) that may interfere with the inflammatory processes                                                                                                                                 Rheumatoid arthritis
  Hydroxychloroquine          Chloroquine analog, lysosomotropic agent;  can elevate endosomal pH and interfere with ACE2 glycosylation                                                                                                         Malaria
  Nitazoxanide                Prototype member of the thiazolides which has antiviral activity and inhibits viral protein expression                                                                                                            Various helminthic, protozoal, and viral infection  
  Azithromycin               Interferes with protein synthesis by inhibiting the  translation of mRNA; possible mechanism in COVID-19 due to enhancement of the action of hydroxychloroquine                                                    Bacterial infections
  Baloxavir                  An enzyme inhibitor targeting the activities of virus polymerase complexes                                                                                                                                         Influenza virus
  Oseltamivir                A competitive inhibitor of neuraminidase; cleaves sialic acid which prevents the release of the new viral particle from the cell                                                                                   Influenza virus
  Tocilizumab (Actemra®)     May potentially combat cytokine release syndrome (CRS) symptoms (e.g., fever, organ failure, death) in severely ill patients                                                                                       Rheumatoid arthritis, severe or life‐threatening chimeric antigen receptor (CAR) T cell‐induced cytokine release syndrome (CRS)
  Avastin (Bevacizumab       Vascular endothelial growth factor inhibitor that binds to receptors on endothelial cells to help drive angiogenesis                                                                                               Certain types of cancer
  Losartan                   Higher angiotensin-converting enzyme 2 expressions following long term treatment with angiotension1 receptor blocker losartan in SARS-CoV-2 infected patients may protect against acute lung injury                Hypertension and diabetic nephropathy
  -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------

Antivirals

The 90% effective concentration (EC90) value of remdesivir against SARS-CoV-2 in Vero E6 cells was 1.76 μM, which suggests that its working concentration is likely to be achieved in non-human primates \[[@REF8]\]. Remdesivir is available for the treatment of ebola virus disease in humans and has shown promising results in animal models for MERS-CoV and SARS-CoV. Therapeutic remdesivir treatment in MERS-CoV inoculated rhesus macaques resulted in the reduction in clinical signs, virus replication, and the absence of lung lesions in 2/6 remdesivir-treated animals along with the reduction in lesion severity in three additional animals. MERS-CoV has a close resemblance to SARS-CoV-2 and the drug is being studied for the treatment of COVID-19 in China and the United States \[[@REF9]\]. Results from a recent open-labeled, nonrandomized trial of remdesivir in 53 COVID-19 patients showed that after up to ten days of compassionate use of remdesivir, 68% of the cohort showed symptoms improvement with only 13% mortality rate at a median follow up of 18 days. It is noteworthy to mention that 34 (64%) patients were already on invasive ventilation before the initiation of the treatment, out of which 20 patients were weaned off the invasive ventilation successfully following the treatment. The adverse effects with remdesivir ranged widely from increased liver enzymes (23%), diarrhea (9%), rash (8%) to more severe conditions being multiple organ failure (6%), septic shock (4%), hypotension (8%) and acute kidney injury (6%) \[[@REF10]\]. In a randomized controlled clinical trial of 1063 patients conducted by the National Institute of Allergy and Infectious Disease (NIAID), remdesivir has shown the efficacy in the early results against advanced COVID-19 (NCT04280705). Patients were randomized into the remdesivir group and placebo group. It was observed that remdesivir was better from the perspective of primary endpoint and time to recovery defined as being well enough for hospital discharge or returning to the normal activity level. Preliminary results of this trial showed 31% faster time to recovery in those patients who received compassionate use of remdesivir as compared to placebo patients (*p* \< 0.001). The median time to recovery was 11 days for remdesivir group compared with 15 days for placebo group. Results were also significant in terms of survival benefit, with 8% mortality in remdesivir group as compared to 11.6% in placebo group (*p* = 0.059) These results support the use of remdesivir for the patients who are hospitalized with COVID-19 and require supplemental oxygen therapy \[[@REF11]\].

The American Center for Disease Control (CDC) in a public document on its website, showed that three patients were treated with remdesivir via compassionate use protocol among the first 12 patients confirmed to have COVID-19 in the United States. All patients reportedly have recovered, but the few side effects like transient gastrointestinal symptoms and aminotransferase elevation were reported, and the authors were unable to weigh the efficacy of remdesivir because of no comparator and confounding treatments, including the concomitant use of corticosteroids in one patient \[[@REF12]\]. A recent update on the efficacy of RDV against COVID-19 by Gilead Sciences also reported that more than 1,700 patients have now been treated with RDV through the expanded access programs \[[@REF13]\]. The ongoing clinical trials on remdesivir are given in Table [2](#TAB2){ref-type="table"}.

###### Characteristics of clinical trials studying remdesivir in patients with COVID-19

  ------------------- ------------ ---------------------- ------------ ------------------------------------------------ -----------
  Clinical trial ID   Status       Study results          Conditions   Interventions                                    Locations
  NCT04302766         Available    No results available   COVID-19     Remdesivir                                       USA
  NCT04280705         Recruiting   No results available   COVID-19     Placebo and remdesivir                           USA  
  NCT04315948         Recruiting   No results available   COVID-19     Remdesivir and other standard care               France  
  NCT04315948         Recruiting   No results available   COVID-19     Drug: remdesivir other: standard of care         France  
  NCT04314817         Recruiting   No results available   COVID-19     Drug: Any drug used to treat COVID-19            France
  NCT04292899         Recruiting   No results available   COVID-19     Drug: remdesivir drug: standard of care          USA
  NCT04292730         Recruiting   No results available   COVID-19     Drug: remdesivir drug: standard of care          USA  
  NCT04321616         Recruiting   No results available   COVID-19     Drug: remdesivir other: (standard of care) soc   Norway
  ------------------- ------------ ---------------------- ------------ ------------------------------------------------ -----------

The combination of lopinavir-ritonavir was used to treat adult hospitalized patients with severe COVID-19. However, treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement: 1.24; 95% confidence interval \[CI\]: 0.90 to 1.72). Mortality at 28 days was similar in the lopinavir-ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, −5.8 percentage points; 95% CI, −17.3 to 5.7) \[[@REF14]\]. Further studies are undergoing to test its efficacy. A fixed dose of the anti-HIV combination, lopinavir-ritonavir, is currently in clinical trials with arbidol or ribavirin but results are not yet available \[[@REF15]\]. Favipiravir, which acts as an alternate substrate leading to lethal RNA transversion mutations producing a nonviable viral phenotype, has also been recently approved for clinical trials in treating the COVID-19 \[[@REF16]\]. The clinical trials on lopinavir and ritonavir are given in Table [3](#TAB3){ref-type="table"}.

###### Characteristics of clinical trials studying lopinavir/ritonavir in patients with COVID-19

  ------------------- ------------ ---------------------- ------------ -------------------------------------------------------------------------------- ---------------
  Clinical trial ID   Status       Study results          Conditions   Interventions                                                                    Locations
   NCT04252885        Recruiting   No results available   COVID-19     Drug: Lopinavir and ritonavir tablets drug: Arbidol                               China
  NCT04307693         Recruiting   No results available   COVID-19     Drug: Lopinavir/ritonavir drug: Hydroxychloroquine sulfate                       South Korea
  NCT02845843         Recruiting   No results available   COVID-19     Drug: Combination of lopinavir /Ritonavir and Interferon beta-1b drug: Placebo   Saudi Arabia
  NCT04276688         Completed    No results available   COVID-19     Drug: Lopinavir/ritonavir drug: Ribavirin drug: Interferon beta-1B               Hong Kong
  NCT04321174         Recruiting   No results available   COVID-19     Drug: Lopinavir/ritonavir                                                        Canada
  NCT04251871         Recruiting   No results available   COVID-19     Drug: lopinavir/ritonavir                                                        China
  NCT04315948         Recruiting   No results available   COVID-19     Drug: remdesivir drug: lopinavir/ritonavir drug: hydroxychloroquine              France
  NCT04351724         Recruiting   No results available   COVID-19     Drug: Chloroquine or hydroxychloroquine drug: Lopinavir/ritonavir                Austria
  NCT04314817         Recruiting   No results available   COVID-19     Drug: Any drug used to treat Covid-19                                            France
  NCT04328012         Recruiting   No results available   COVID-19     Drug: Lopinavir/ritonavir drug: Hydroxychloroquine sulfate drug: Placebos        United States
  NCT04343768         Completed    No results available   COVID-19     Drug: Hydroxychloroquine drug: Lopinavir / ritonavir                             Iran
  ------------------- ------------ ---------------------- ------------ -------------------------------------------------------------------------------- ---------------

Corticosteroids

The use of corticosteroids for the treatment of coronavirus infections is controversial. While it reduces the immunological damage, viral rebound, and adverse events remain the major concerns \[[@REF17]\]. The use of corticosteroids in SARS patients has been associated with increased viral load, while side effects like avascular necrosis (seen in 9% of patients in a cohort in Hong Kong) and opportunistic infections like aspergillosis have been reported \[[@REF18]\]. A significantly higher concentration of plasma viral RNA concentration was reported in the second and third weeks of illness in patients treated with hydrocortisone (n=9) as compared to those receiving placebo (n=7; p=0.023) \[[@REF19]\]. However, in another study, better results were seen in patients of SARS-CoV (n = 190) treated with early high-dose steroids in combination with a quinolone (n=60) (zero deaths; meantime to discharge: 20.7 ± 4.6) vs other three treatment groups (n = 40,30,60) (two or more deaths in each group; meantime to discharge: 24.8 ± 5.5, 24.8 ± 6.4, 22.4 ± 5.9).

Preliminary reports from the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial (n=2104, received dexamethasone at a dose of 6mg once daily per oral/intravenous vs n=4321 patients received usual care alone) showed that dexamethasone showed improved survival in COVID-19 patients. Among the patients receiving usual care alone, the 28 days mortality in those requiring ventilation, requiring oxygen only, and in those not requiring any respiratory intervention was 41%, 25%, and 13%, respectively. Even though no benefit was seen among the patients not requiring respiratory support (rate ratio 1.22; 95% confidence interval \[CI\] 0.86-1.75; *p* = 0.14), but in the ventilated patients with COVID-19, dexamethasone decreased the deaths by one-third (rate ratio 0.65; 95% CI 0.48-0.88; *p *= 0.0003), and by one-fifth in the patients requiring oxygen only (rate ratio 0.80; 95% CI 0.67-0.96; *p *= 0.0021). These results indicated that for the prevention of one death, eight patients requiring ventilation needed to treat while this number was 25 in patients requiring oxygen only. These promising results mean the role of dexamethasone and possibly other steroids should be explored further for the treatment of COVID-19 patients \[[@REF20]\]. The clinical trials on corticosteroids are given in Table [4](#TAB4){ref-type="table"}.

###### Characteristics of clinical trials studying corticosteroid in patients with COVID-19

  ------------------- ------------ ---------------------- ------------ -------------------------------------------------------------------- -----------
  Clinical trial ID   Status       Study results          Conditions   Interventions                                                        Locations
  NCT04355637         Recruiting   No results available   COVID-19     Drug: Inhaled budesonide                                             Spain
  NCT04344288         Recruiting   No results available   COVID-19     Drug: Prednisone                                                     France
  NCT04327401         Recruiting   No results available   COVID-19     Drug: Dexamethasone                                                  Brazil
  NCT04355247         Recruiting   No results available   COVID-19     Methylprednisolone 80 milligrams/milliliters injectable suspension   Rico
  NCT04343729         Recruiting   No results available   COVID-19     Methylprednisolone sodium succinate Placebo solution                 Brazil
  NCT02517489         Recruiting   No results available   COVID-19     Drug: Hydrocortisone drug: Placebo                                   France
  ------------------- ------------ ---------------------- ------------ -------------------------------------------------------------------- -----------

Janus kinase inhibitor

Baricitinib has anti-inflammatory action and possible ability to inhibit viral entry into the cells \[[@REF21]\]. It is a Janus kinase (JAK) inhibitor that binds to the cyclin G-associated kinase, a regulator of endocytosis. Baricitinib in therapeutic dose (either as 2mg or 4mg once daily) is enough to inhibit AP2-associated protein kinase 1 (AAK1), a regulator of the endocytosis process, which is implicated in the cellular viral entry process. Baricitinib can disrupt AAK1 causing the interruption of viral entry into the cell and intracellular assembly of virus particles, which makes it a potential drug for COVID-19 \[[@REF22]\]. The clinical trials on JAKs are given in Table [5](#TAB5){ref-type="table"}.

###### Characteristics of clinical trials studying baricitinib in patients with COVID-19

  ------------------- ------------ ---------------------- ------------ ------------------------------------------------------------------------------ -----------
  Clinical trial ID   Status       Study Results          Conditions   Interventions                                                                  Locations
  NCT04321993         Recruiting   No results available   COVID-19     Drug: Lopinavir/ritonavir drug: Hydroxychloroquine sulfate drug: Baricitinib   Canada
  NCT04401579         Recruiting   No results available   COVID-19     Other: Placebo drug: Remdesivir drug: Baricitinib                              USA
  ------------------- ------------ ---------------------- ------------ ------------------------------------------------------------------------------ -----------

Antiprotozoal drugs

Nitazoxanide, an antiprotozoal drug, has antiviral potential against a wide range of viruses, including human and animal coronaviruses. It has also inhibited viral replication at a low-micro molar concentration in Vero E6 cells, with half-maximal effective concentration (EC50) of 2.12μM \[[@REF14]\]. Ivermectin also acts as an anti-viral by inhibiting importin α/β1 and integrase proteins involved in viral replication \[[@REF23]\]. A single treatment with ivermectin has shown to reduce SARS-CoV-2 RNA by ∼5000-fold at 48 hours in cell culture \[[@REF24]\].

###### Characteristics of a clinical trial studying nitazoxanide in patients with COVID-19

  ------------------- ------------ ---------------------- ------------ ---------------------------------------- -----------
  Clinical trial ID   Status       Study Results          Conditions   Interventions                            Locations
  NCT04341493         Recruiting   No results available   COVID-19     Nitazoxanide 500 Mg Hydroxychloroquine   Mexico
  ------------------- ------------ ---------------------- ------------ ---------------------------------------- -----------

Interleukin receptor blocker

Plasma levels of Interleukin-2 (IL-2), IL-7, and IL-10 were found to be higher in more sick patients and those admitted in the intensive care unit \[[@REF25]\]. Tocilizumab is a recombinant humanized monoclonal antibody specific for the interleukin-6 (IL-6) receptor and is used for the treatment of cytokine release syndrome. In a retrospective observational study involving twenty patients with severe or critical COVID-19, treatment with tocilizumab in addition to lopinavir, methylprednisolone, other symptom relievers, and oxygen therapy, resulted in body temperature of all the patients returning to normal on the first day of receiving tocilizumab and significant relief of clinical symptoms synchronously in the following days. After treatment, oxygen intake was lowered in 15/20 patients and one patient did not need oxygen therapy while CT scan lesions were absorbed in nineteen patients. No adverse events were reported during treatment with tocilizumab \[[@REF26]\]. Ongoing clinical trials on tocilizumab are given in Table [7](#TAB7){ref-type="table"}.

###### Characteristics of clinical trials studying tocilizumab in patients with COVID-19

  ------------------- ------------ ---------------------- ------------ ------------------------------------------------------------------------------ ---------------
  Clinical trial ID   Status       Study results          Conditions   Interventions                                                                  Locations
  NCT04335071         Recruiting   No results available   COVID-19     Drug: Tocilizumab drug: Placebo                                                Switzerland
  NCT04310228         Recruiting   No results available   COVID-19     Drug: Favipiravir combined with tocilizumab                                    China
  NCT04359667         Recruiting   No results available   COVID-19     Drug: Tocilizumab 20 milligrams/milliliters intravenous solution \[ACTEMRA\]   Croatia
  NCT04339712         Recruiting   No results available   COVID-19     Drug: Anakinra drug: Tocilizumab                                               Greece
  NCT04335305         Recruiting   No results available   COVID-19     Drug: Tocilizumab biological: Pembrolizumab (MK-3475)                          Spain
  NCT04361552         Recruiting   No results available   COVID-19     Other: Best practice biological: Tocilizumab                                   United States
  NCT04330638         Recruiting   No results available   COVID-19     Drug: Anakinra drug: Siltuximab drug: Tocilizumab                              Belgium  
  ------------------- ------------ ---------------------- ------------ ------------------------------------------------------------------------------ ---------------

COVID-19-specific convalescent plasma and immunoglobulin infusion

The use of convalescent plasma in severe acute respiratory infections (SARI) has shown favorable results in the past, with the mortality rate reduced by 75% in those who received convalescent plasma among all viral etiologies such as SARS coronavirus (SARS-CoV), Spanish influenza A (H1N1), Avian influenza A(H5N1), and influenza A (H1N1). These studies did not report any major adverse events \[[@REF27]\]. COVID-19-specific plasma collected from five recovered SARS-COV2 patients with age ranges from 18 to 60, has shown positive results in a small case series of five critically ill patients diagnosed with COVID-19 who were under mechanical ventilation, and had a high viral load despite receiving antivirals and methylprednisolone. Among a total of five patients (age range: 36-73) who were treated with plasma, viral load reduction has been noted on the same day with continuous improvement over several days (1-12days) followed by gradual resolution of symptoms. Four out of five patients no longer required respiratory support on day nine post plasma transfusion and 3/5 patients were discharged home after hospital stay ranging from 51-55 days. Hospitalization was continued for 2/5 patients with a total of 37 days of hospital stay \[[@REF28]\]. Similarly, the use of a high dose of intravenous immunoglobulin G (IVIG) obtained from healthy donors' serum in patients (n = 3) with the diagnosis of COVID-19 severe type has also shown effective results. The fever subsided the very next day in two cases (age: 34 and 35) and the same day in the third patient (age 56), accompanied by symptoms resolution over a couple of days with no adverse events reported. This indicates that the clinical outcome of patients with COVID-19 can be improved if the disease progression is halted down by administering high dose IVIG in a timely fashion \[[@REF29]\]. Additional data and clinical trials on high dose IVIG in COVID-19 patients are warranted. The ongoing clinical trials are given in Table [8](#TAB8){ref-type="table"}.

###### Characteristics of clinical trials studying specific convalescent plasma and immunoglobulin infusion in patients with COVID-19

  ------------------- ------------ ---------------------- ------------ -------------------------------------------------------------------------------------------------------------------------------------- ---------------
  Clinical trial ID   Status       Study results          Conditions   Interventions                                                                                                                          Locations
  NCT04358783         Recruiting   No results available   COVID-19     Biological: plasma Other: Best available therapy                                                                                       Mexico
  NCT04362176         Recruiting   No results available   COVID-19     Biological: pathogen reduced SARS-CoV-2 convalescent plasma biological: Placebo                                                        United States
  NCT04346589         Recruiting   No results available   COVID-19     Biological: Anti-coronavirus antibodies (immunoglobulins) obtained with  double-filtration plasmapheresis from convalescent patients   Italy
  ------------------- ------------ ---------------------- ------------ -------------------------------------------------------------------------------------------------------------------------------------- ---------------

Angiotensin receptor blockers and ibuprofen

Angiotensin-converting enzyme 2 (ACE2) is a binding site for SARS-CoV-2. The binding of SARS-CoV-2 to ACE2 leads to the downregulation of ACE2 resulting in increased angiotensin production by Angiotensin-converting enzyme (ACE) as there is less ACE2 to convert angiotensin to the vasodilator heptapeptide angiotensin 1-7. This increased angiotensin causes increased angiotensin receptor 1 (AT1R) stimulation resulting in increased pulmonary vascular permeability leading to lung injury. It has been hypothesized that AT1R antagonists like Losartan increase ACE2 expression and prevent lung injury in COVID-19 patients \[[@REF30]\]. However, another hypothesis suggests that cellular entry of SARS-CoV-2 is facilitated by the up-regulation of ACE2 caused by AT1R antagonist use and hence can be harmful in COVID-19 patients. Similarly, non-steroidal anti-inflammatory drugs (NSAIDs) like Ibuprofen also acts by upregulating ACE2 \[[@REF31]\]. Ongoing clinical trials are given in Table [9](#TAB9){ref-type="table"}.

###### Characteristics of clinical trials studying losartan in patients with COVID-19

  ------------------- ------------ ---------------------- ------------------------ --------------------------------------------------------------------------- ---------------
  Clinical trial ID   Status       Study results          Conditions               Interventions                                                               Locations
  NCT04330300         Recruiting   No results available   Hypertension, COVID-19   Drug: ACE inhibitor other antihypertensive agents                           Ireland
  NCT04340557         Recruiting   No results available   COVID-19                  Losartan                                                                   United States
   NCT04335786        Recruiting   No results available   COVID-19                 Drug: Valsartan (diovan) drug: Placebo oral tablet                          Netherlands
   NCT04312009        Recruiting   No results available   COVID-19                 Drug: Losartan other: Placebo                                               United States
  NCT04311177         Recruiting   No results available   COVID-19                 Drug: Losartan other: Placebo                                               United States
  NCT04328012         Recruiting   No results available   COVID-19                 Drug: Lopinavir/ritonavir Drug: Hydroxychloroquine Sulfate Drug: Losartan   United States
  ------------------- ------------ ---------------------- ------------------------ --------------------------------------------------------------------------- ---------------

Antimalarial drug and its combinations

The 90% effective concentration (EC90) value of chloroquine against the SARS-CoV-2 in Vero E6 cells is 6.90 μM, which can be achieved clinically, as has already been demonstrated in the plasma of rheumatoid arthritis patients \[[@REF32]\]. In an open-label non-randomized clinical trial of hydroxychloroquine (HCQ) (n = 36), 70% of HCQ treated patients (n=14/20) were virologically cured vs 12.5% in the control group (n=2/16) (*p* = 0.001) at day six post inclusion while 100% patients treated with HCQ plus Azithromycin (n = 6/6) were virologically cured vs 57.1% in patients receiving HCQ alone (*n* = 8/14) \[[@REF32]\]. The limitations of this study were its small sample size, limited long-term outcome follow-up, and dropout of six patients from the study. Hence a larger sample size study is essential to investigate and find out the efficacy of HCQ in the treatment of COVID-19 \[[@REF33]\]. However, in a recent study, hydroxychloroquine was not effective against COIVD-19 patients and has been revoked from the emergency use against COVID-19 patients due to safety concerns. Ongoing clinical trials are given in Table [10](#TAB10){ref-type="table"}.

###### Characteristics of clinical trials studying chloroquine and hydroxychloroquine in patients with COVID-19

  ------------------- ------------ ---------------------- ------------ ----------------------------------------------------------------------------------------------------------------- ---------------
  Clinical trial ID   Status       Study results          Conditions   Interventions                                                                                                     Locations
  NCT04316377         Recruiting   No results available   COVID-19     Drug: Hydroxychloroquine sulfate                                                                                   Norway
  NCT04341727         Recruiting   No results available   COVID-19     Drug: Hydroxychloroquine sulfate drug: Azithromycin Drug: Chloroquine sulfate                                     United States
  NCT04346667         Recruiting   No results available   COVID-19     Drug: Hydroxychloroquine sulfate Regular dose. Drug: Hydroxychloroquine sulfate loading dose. Drug: Chloroquine   Pakistan
  NCT04322396         Recruiting   No results available   COVID-19     Drug: Azithromycin drug: Hydroxychloroquine                                                                       Denmark
  NCT04351191         Recruiting   No results available   COVID-19     Drug: Hydroxychloroquine sulfate regular dose. Drug: Hydroxychloroquine sulfate loading dose                      Pakistan
  NCT04325893         Recruiting   No results available   COVID-19     Drug: Hydroxychloroquine drug: Placebo                                                                            France  
  NCT04353037         Recruiting   No results available   COVID-19     Drug: Group a hydroxychloroquine drug: Group b control                                                            United States
  NCT04324463         Recruiting   No results available   COVID-19     Drug: Azithromycin drug: Hydroxychloroquine or chloroquine                                                        Canada
  NCT04321278         Recruiting   No results available   COVID-19     Drug: Hydroxychloroquine + azithromycin drug: Hydroxychloroquine                                                  Brazil
  NCT04344951         Recruiting   No results available   COVID-19     Drug: Chloroquine phosphate 200mg tablets                                                                         Greece
  NCT04342221         Recruiting   No results available   COVID-19     Drug: Hydroxychloroquine sulfate drug: placebo                                                                    Germany
  NCT04351724         Recruiting   No results available   COVID-19     Drug: Chloroquine or hydroxychloroquine drug: Lopinavir/ritonavir                                                 Austria
  ------------------- ------------ ---------------------- ------------ ----------------------------------------------------------------------------------------------------------------- ---------------

Conclusions
===========

Collaborative global efforts are underway to control the COVID-19 pandemic. Many clinical trials are underway. These trials are different in study structure, the severity of the disease, the duration of the treatment, and the dosing of drugs in the target population. These trials are also different in the quality of the reported information. Many studies are going in parallel, suggesting that the scientific community is working hard to come up with an effective treatment for COVID-19. Few drugs like remdesivir and dexamethasone have demonstrated positive early results against COVID-19 in clinical trials and their efficacy has also been observed in pre-clinical and clinical studies, but their use against COVID-19 should be based on the severity of patient clinical status and ethical approval from randomized clinical trials. Efficacy and safety data from further studies with larger sample size, blinded, randomized design, and longer follow-up are needed urgently.
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